

JUBILANT BIOSYS (SINGAPORE) PTE LTD
Balance Sheet

As at 31st Mar	Notes No	2014 USD	2014 INR (' In Thousands)	2013 USD	2013 INR (' In Thousands)
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share capital	1	1,371,501	68,559	1,356,501	67,754
Reserves & surplus	2	(61,175)	9,942	(49,315)	3,214
Money received against share warrants				-	
		1,310,326	78,502	1,307,186	70,967
Current liabilities					
Trade payables	3	4,722	283	-	-
Other current liabilities	4	159	10	6,549	356
		4,881	292	6,549	356
		1,315,207	78,794	1,313,734	71,324
II. ASSETS					
Non-current investments					
Non-current investments	5	1,306,552	78,276	1,306,552	70,933
Long-term loans and advances	6	3,971	238	4,026	220
		1,310,523	78,513	1,310,578	71,153
Current assets					
Cash & bank balances	7	4,683	281	3,156	171
		4,683	281	3,156	171
Total		1,315,207	78,794	1,313,734	71,324

Rajneesh Gupta
Head Accounts
Place : Noida
Date : 22nd May 2014

JUBILANT BIOSYS (SINGAPORE) PTE LTD
Statement of Profit and Loss

For the year ended 31st March,	Notes No	2014	2014	2013	2013
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES					
Other expenses	8	11,806	713	12,464	677
Total expenses		11,806	713	12,464	677
Profit before exceptional items and tax		(11,806)	(713)	(12,464)	(677)
Exceptional items	9	54	3	(48)	(3)
Profit for the Year		(11,860)	(716)	(12,415)	(675)

Rajneesh Gupta
Head Accounts
Place : Noida
Date : 22nd May 2014

JUBILANT BIOSYS (SINGAPORE) PTE LTD
Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized				
Equity Share Capital	-	-	-	-
Issued & Subscribed				
1,371,501 equity shares of USD 1 each (Previous Year 1,356,501 equity shares of USD 1 each)	-	-	-	-
Paid up				
1,371,501 equity shares of USD 1 each (Previous Year 1,356,501 equity shares of USD 1 each)	1,371,501	68,559	1,356,501	67,754
	1,371,501	68,559	1,356,501	67,754

- 1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.
2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential
3) The details of shareholders holding more than 5% shares in the company :

As at 31st Mar	2014	2014	2013	2013
Name of the shareholder	No of shares	% held	No of shares	% held
Jubilant Biosys (BVI) Ltd., British Virgin Islands - the Holding Company	1,371,501	100%	1,356,501	100%

- 4) The reconciliations of number of shares outstanding at beginning and at the end of reporting period

As at 31st Mar	2014	2014	2013	2013
Particulars	No	INR (' In Thousands)	No	INR (' In Thousands)
Numbers of shares at the beginning	1,356,501	67,722	1,351,001	67,448
Add: Shares issued during the year	15,000	837	5,500	306
Numbers of shares at the end	1,371,501	68,559	1,356,501	67,754

- 5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates
Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st Mar	2014	2014	2013	2013
Particulars	No	INR (' In Thousands)	No	INR (' In Thousands)
Jubilant Biosys (BVI) Ltd., British Virgin Islands - the Holding Company 1,371,501 equity shares of USD 1 each (Previous Year 1,356,501 equity shares of USD 1 each)	1,371,501	68,559	1,356,501	67,754

JUBILANT BIOSYS (SINGAPORE) PTE LTD
Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	5,610	-	1,129
Foreign Currency Translation Reserve During the Year	-	7,445	-	4,481
	-	13,055	-	5,610
Surplus as per P&L Account				
As per last Balance Sheet	(49,315)	(2,396)	(36,900)	(1,722)
Add: Net Profit after tax transferred from Statement of Profit and Loss	(11,860)	(716)	(12,415)	(674)
	(61,175)	9,942	(49,315)	3,214
3. TRADE PAYABLES				
Trade payables-others	4,722	283	-	-
	4,722	283	-	-
4. OTHER CURRENT LIABILITIES				
Other payables	159	10	6,549	356
	159	10	6,549	356
5. NON-CURRENT INVESTMENTS				
Investment in Subsidiary/ Fellow subsidiaries Companies				
Jubilant Biosys Limited	1,306,552	78,276	1,306,552	70,933
295,600 shares (previous years 295,600 shares) of Rs. 10 each				
	1,306,552	78,276	1,306,552	70,933
6. LONG TERM LOANS AND ADVANCES				
Security deposits(unsecured, considered good)	3,971	238	4,026	219
	3,971	238	4,026	219
7. CASH AND BANK BALANCES				
Cash and cash equivalents				
Balances with banks:				
- On current accounts	4,683	281	3,156	171
	4,683	281	3,156	171
8. OTHER EXPENSE				
Auditors Remuneration - As Auditors	3,824	230	4,148	225
Legal , professional & consultancy charges	7,682	465	7,742	421
Directors' sitting fees	159	10	474	26
Bank Charges	140	8	100	5
	11,806	713	12,464	677
9. EXCEPTIONAL ITEMS				
Foreign Exchange Gain/Loss	54	3	(48)	(3)
	54	3	(48)	(3)

JUBILANT BIOSYS (SINGAPORE) LTD
CASH FLOW STATEMENT

For the year ended 31st March,

	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
A. Cash flows from operating activities				
Net income before minority interest	(11,860)	(716)	(12,415)	(675)
Adjustments to reconcile net income to net cash provided by operating activities				
Unrealised (gain)/loss on exchange (including mark-to-market on currency and interest rate swaps)	-	-	(48)	(3)
	-	-	(48)	(3)
Operating profit before working capital changes	(11,860)	(716)	(12,464)	(677)
Adjustments for :				
(Increase)/Decrease in trade and other receivables	54	3	3,461	188
Increase/(Decrease) in trade and other payables	(1,667)	(101)	2,733	149
Net cash inflow/(outflow) in course of operating activities	(13,473)	(814)	(6,270)	(341)
C. Cash flow arising from financing activities :				
Proceeds from issue of share capital(including share premium & net of share issue expenses)	15,000	906	5,500	299
Net cash inflow/(outflow) in course of financing activities	15,000	906	5,500	299
D. Foreign currency translation difference arising on consolidation		17		13
Net Increase in cash & cash equivalents (A+B+C+D)	1,527	109	(770)	(28)
Add: cash & cash equivalents at the beginning of year(including balance in dividend accounts)	3,156	171	3,926	200
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	4,683	281	3,156	171

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-"Cash Flow Statements".

Rajneesh Gupta

Head Accounts

Place : Noida

Date : 22nd May, 2014